C4X Discovery Holdings PLC - Manchester-based developer of drug discoveries - Says it has made continued progression across its drug discovery portfolio. Says it is in advanced stage commercial discussions for its NRF2 activator programme for inflammatory diseases with a deal anticipated in the second half of 2022. Also says its MALT-1 inhibitor programme for haematological and solid tumours has compounds, that match the leading clinical candidate in terms of in vitro and in vivo profile, is now moving towards identifying a ‘best-in-class shortlist of compounds’.

‘Our partnered portfolio has continued to deliver over the past few months, most notably with our first milestone payment from Sanofi for our oral IL-17a inhibitor to treat inflammatory diseases [in July]. This was an important further step in demonstrating the commercial value of C4XD’s expertise, approach to drug discovery, and its business model. Looking ahead, with partnering discussions advancing for our third programme, NRF2, we remain well positioned for growth as multiple partnerable assets in the pipeline continue strong progression,’ said Chief Executive Officer Clive Dix.

Current stock price: 27.00 pence

12-month change: down 14%

Copyright 2022 Alliance News Limited. All Rights Reserved.